Skip to main content
Tumour bank

How to easily participate in cancer research? 

The Institut Bordet Tumour Bank or Tumour Biobank is a collection of samples of human body material (tumour tissue residue, blood samples) and of associated data preserved in optimum conditions for their future use in research. It constitutes a crucial link between diagnosis and fundamental, translational and clinical research. Its activity is subject to strict legislation.

The development of personalised medicine and of immunotherapy in oncology requires the exploration of new biomarkers identifiable in tumour tissue, but also in blood. The role of the Tumour Bank is to collect and supply to scientific research laboratories very high quality, diversified, biological samples in sufficient quantity, accompanied by complete clinical data to enable them to carry out their research. The objective is to understand how tumour ‘machinery’ operates and the strategy that allows it to escape the vigilance and immune defences of its host.

The Tumour Bank forms part of the Anatomical Pathology Department, enabling full and accurate analysis of tumours by pathologists prior to their preservation. It also forms an integral part of other Belgian biobanks – the Cancer Register Virtual Catalogue, BWB (Wallonia-Brussels BioBank) and of 2 European biobanks: the BBMRI and ESBB. Contact via these networks between different Belgian and international research teams facilitates the establishment of links and skill sharing.

The Institut Bordet Tumour Bank has been ISO90001 certified since 2012 – a guarantee of quality. The robust system put in place for the quality control of our samples enables us to support numerous research projects every year. This is evidenced in the quality of the scientific publications that result from these.

Research

The Tumour Bank not only supplies biological material, it also develops its own scientific projects.

 

Project 1

Recognition of neutrophils and measurements of the protein expression of candidates able to affect their functions in non-small-cell lung cancer

Project 2

Unravelling the role of epitranscriptomics in breast cancer

Project 3

Robustness of next generation sequencing on older FFPE blocks

Project 4

Characterisation of the microbiota in colorectal metastases: nature and impact on the tumour immune microenvironment, progression of the disease and response to treatment.  

Project 5

HPV infection in oesophagial adenocarcinoma

Project 6

Analysis of astrocyte subtypes, microglia and macrophages in brain metastases

Project 7

MOLECULAR CHARACTERIZATION OF INTRATUMOR HETEROGENEITY OF DIFFERENT BREAST CANCER SUBTYPES AND THEIR MICROENVIRONMENT USING MULTIOMIC PLATFORMS

Project 8

HIGH-THROUGHPUT TRUTHING OF MICROSCOPE SLIDES TO VALIDATE ARTIFICIAL INTELLIGENCE ALGORITHMS ANALYZING DIGITAL SCANS OF SAME SLIDES

Project 9

INVESTIGATING THE RELEVANCE OF TROP2 AS A POTENTIAL MARKER OF EPITHELIAL REGENERATION IN HUMAN INFLAMMATORY BOWEL DISEASES

Project 10

CYTOTOXICITY MECHANISMS LINKED TO PDE3A IN GASTROINTESTINAL STROMAL TUMOURS: IN VIVO AND IN VITRO PRECLINICAL STUDIES

Project 11

CONTRIBUTION TO THE STUDY OF THE IMMUNE ENVIRONMENT OF PANCREATIC CANCERS IN TREATMENT-NAÏVE PATIENTS AND THOSE HAVING RECEIVED DIFFERENT TYPES OF NEOADJUVANT THERAPY

Project 12

ACTIVATING PHOSPHORYLATION OF CDK4: USE TO PREDICT TUMOUR RESPONSIVENESS TO CDK4 INHIBITORY DRUGS IN ORDER TO EXTEND THESE DRUGS TO CANCERS LACKING EFFICIENT THERAPIES

Team

Head of the Anatomical Pathology Department, Human Body Material Manager
Pr D. Larsimont

Tumour Bank Coordinator
Dr Sc L. Craciun

Technologist
A. Spinette

Publications

Tumor Banks: A Quality Control Scheme Proposal

Craciun L, Spinette SA, Rassy M, Salgado R, de Wind A, Demetter P, Verset L, Gomez-Galdon M, Chintinne M, Sirtaine N, de St Aubain N, Laios I, Roy F, Larsimont D.

Front Med (Lausanne). 2019

 

Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer

Garaud S, Buisseret L, Solinas C, Gu-Trantien C, de Wind A, Van den Eynden G, Naveaux C, Lodewyckx JN, Boisson A, Duvillier H, Craciun L, Ameye L, Veys I, Paesmans M, Larsimont D, Piccart-Gebhart M, Willard-Gallo K.

JCI Insight. 2019

BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer

Solinas C, Marcoux D, Garaud S, Vitória JR, Van den Eynden G, de Wind A, De Silva P, Boisson A, Craciun L, Larsimont D, Piccart-Gebhart M, Detours V, t'Kint de Roodenbeke D, Willard-Gallo K

Cancer Lett. 2019

Reprogramming of Energy Metabolism: Increased Expression and Roles of Pyruvate Carboxylase in Papillary Thyroid Cancer

Strickaert A, Corbet C, Spinette SA, Craciun L, Dom G, Andry G, Larsimont D, Wattiez R, Dumont JE, Feron O, Maenhaut C.

Thyroid, 2019.

FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer

De Silva P, Garaud S, Solinas C, de Wind A, Van den Eyden G, Jose V, Gu-Trantien C, Migliori E, Boisson A, Naveaux C, Duvillier H, Craciun L, Larsimont D, Piccart-Gebhart M, Willard-Gallo K

EBioMedicine. 2019

Distinctive Desmoplastic 3D Morphology Associated With BRAFV600E in Papillary Thyroid Cancers

Tarabichi M, Antoniou A, Le Pennec S, Gacquer D, de Saint Aubain N, Craciun L, Cielen T, Laios I, Larsimont D, Andry G, Dumont JE, Maenhaut C, Detours V

J Clin Endocrinol Metab. 2018

Inflammatory Stroma of Lymphoepithelioma-like Carcinoma of the Cervix: Immunohistochemical Study of 3 Cases and Review of the Literature

Philippe A, Rassy M, Craciun L, Naveaux C, Willard-Gallo K, Larsimont D, Veys I.

Int J Gynecol Pathol. 2018

 

 Scientific publications

Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.

Authors : De Caluwé A, Buisseret L, Poortmans P, Van Gestel D, Salgado R, Sotiriou C, Larsimont D, Paesmans M, Craciun L, Drisis S, Vandekerckhove C, Reyal F, Veys I, Eiger D, Piccart-Gebhart M, Romano E, Ignatiadis M
Year : 2021
Journal : BMC Cancer
Volume : 21
Pages : 899

Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment.

Authors : Boisson A, Noël G, Saiselet M, Rodrigues-Vitória J, Thomas N, Fontsa ML, Sofronii D, Naveaux C, Duvillier H, Craciun L, Larsimont D, Awada A, Detours V, Willard-Gallo K, Garaud S
Year : 2021
Journal : Front Mol Biosci
Volume : 8
Pages : 673042

Transcriptional output, cell-type densities, and normalization in spatial transcriptomics.

Authors : Saiselet M, Rodrigues-Vitória J, Tourneur A, Craciun L, Spinette A, Larsimont D, Andry G, Lundeberg J, Maenhaut C, Detours V
Year : 2021
Journal : J Mol Cell Biol
Volume : 12
Pages : 906-908

Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel.

Authors : Bregni G, Sticca T, Camera S, Akin Telli T, Craciun L, Trevisi E, Pretta A, Kehagias P, Leduc S, Senti C, Deleporte A, Vandeputte C, Saad ED, Kerger J, Gil T, Piccart-Gebhart M, Awada A, Demetter P, Larsimont D, Hendlisz A, Aftimos P, Sclafani F
Year : 2020
Journal : Acta oncol (Stockholm)
Volume : 59
Pages : 1438-1446

Infiltrative tumour growth pattern correlates with poor outcome in oesophageal cancer.

Authors : Anciaux M, Demetter P, de Wind R, Gomez Galdon M, Vande Velde S, Lens G, Craciun L, Deleruelle A, Larsimont D, Lenaerts T, Sclafani F, Deleporte A, Donckier V, Hendlisz A, Vandeputte C
Year : 2020
Journal : BMJ Open Gastroenterol
Volume : 7